Explore

Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
OrganaBio Acquires Excellos to Expand Cell Therapy Manufacturing Across U.S.

OrganaBio Acquires Excellos to Expand Cell Therapy Manufacturing Across U.S.

OrganaBio Acquires Excellos to Expand Cell Therapy Manufacturing Across U.S.
Trendline Trendline
Bora Acquires MacroGenics Facility for $122.5M to Expand U.S. Presence

Bora Acquires MacroGenics Facility for $122.5M to Expand U.S. Presence

Bora Acquires MacroGenics Facility for $122.5M to Expand U.S. Presence
Trendline Trendline
PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability
Trendline Trendline
Takeda Reports FY2025 Results and FY2026 Outlook with Strong Pipeline Progress

Takeda Reports FY2025 Results and FY2026 Outlook with Strong Pipeline Progress

Takeda Reports FY2025 Results and FY2026 Outlook with Strong Pipeline Progress
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5 Million
Trendline Trendline
Angelini Pharma Enters U.S. Market with $4.1 Billion Acquisition

Angelini Pharma Enters U.S. Market with $4.1 Billion Acquisition

Angelini Pharma Enters U.S. Market with $4.1 Billion Acquisition
Trendline Trendline
MacroGenics to Sell Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million

MacroGenics to Sell Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million

MacroGenics to Sell Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million
Trendline Trendline
Bora Group to Acquire MacroGenics' Manufacturing Operations for $122.5 Million

Bora Group to Acquire MacroGenics' Manufacturing Operations for $122.5 Million

Bora Group to Acquire MacroGenics' Manufacturing Operations for $122.5 Million
Trendline Trendline
Optum Rx Introduces Transparent PBM Model to Enhance Cost Clarity for Clients

Optum Rx Introduces Transparent PBM Model to Enhance Cost Clarity for Clients

Optum Rx Introduces Transparent PBM Model to Enhance Cost Clarity for Clients
Trendline Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5M

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5M

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5M